Willkie represented Stanley Capital in its agreement to acquire Noden Pharma DAC and Noden USA.
On July 30, private equity firm Stanley Capital, announced that it had entered into a definitive agreement to acquire Noden Pharma DAC, a leading specialty pharmaceutical company in the cardiovascular space, from PDL BioPharma, Inc.
The transaction is expected to close by early August 2020 and is subject to certain customary closing conditions. The total value of the transaction will result in payments to PDL of up to $48.25 million in cash.
Noden is a Dublin-headquartered global specialty pharmaceutical company, focused on providing unique, complex to manufacture prescription medicines in the cardiovascular space for patients who are intolerant to mainstream treatments.
Stanley Capital will work alongside Noden’s management team to execute an identified and active pipeline of add-on acquisitions to help expand the company’s portfolio of essential drugs. The acquisitions will be financed from a mixture of committed funding facilities, and new investors, as the Noden platform grows.
The multidisciplinary cross-border Willkie deal team was led by Corporate & Financial Services partners Gavin Gordon, Claire James and Sebastian Fitzgerald and included associates Amelia Doughty and Megan Gairns.